FDA Cracks Down on Unapproved GLP-1 Weight-Loss Drugs: Hims & Hers in the Crosshairs

The FDA is cracking down on Hims & Hers and other marketers of non-FDA-approved GLP-1 weight-loss drugs, including restricting advertising and sending warning letters. The agency aims to combat claims that unapproved drugs are generic versions of approved drugs. This move follows a series of warning letters sent last fall.